Apex Labs has been granted approval by Health Canada for the first North American take-home multi-dose psilocybin clinical trial evaluating the safety and efficacy of APEX-52...
New data has revealed that a single 25mg dose of COMPASS Pathways’ COMP360 psilocybin in combination with psychological support had a significant impact in reducing symptoms...
Small Pharma has received approval to carry out a first-in-human Phase 1 trial with its injectable deuterated DMT candidate – SPL028 – from the UK Medicines...
The University of Guelph (UoG) has announced that it is one of the first universities to be granted a licence by Health Canada to cultivate psychedelic...
A researcher at Cornell University is using optical microscopy and other tools to map the brain’s neural response to psychedelics.
Algernon Pharmaceuticals has entered an Investigator-Initiated Clinical Trial Agreement with Yale University to investigate multiple intravenous doses of DMT for the treatment of depression.
Clairvoyant has received regulatory approval for its Phase 2 trial investigating psilocybin for the treatment of alcohol use disorder (AUD).
LOVE Pharma’s trial will be exploring psilocybin-assisted therapy for cannabis use disorder (CUD), with Johns Hopkins University School of Medicine’s Dr Albert Garcia-Romeu serving as head...
The first patient has now been dosed in IntelGEnx and atai Life Sciences’ Phase 1 clinical trial to investigate buccal VLS-01 – a buccal film containing...
Numinus Wellness is developing an innovative method of delivery for psilocybin in clinical trials and research.